The PI's preclinical research program seeks to understand how activation of peripheral immune cells and central nervous system microglia and astrocytes triggers a cascade of events leading to neuronal activation and pathological pain states. This current research focus is directly relevant to her long-term goals of understanding (a) immune-neural interactions and (b) endogenous pain modulation systems. The proposed project is a request for a K02 award for the PI to develop skills now required by new results in programmatic investigations of pathological pain states. The 2 animal models employed induce clinically relevant exaggerated pain states by: (a) peri-spinal administration of HIV-1 gp 120 and (b) sciatic inflammatory neuropathy. Extensive evidence indicates that peripheral immune cells and spinal immune-like glial cells play critical roles in the creation and maintenance of exaggerated pain phenomena. Of the substances released by these cells upon activation, the strongest evidence to date points to the proinflammatory cytokines tumor necrosis factor, interleukin-1, and interleukin-6. These signaling molecules are key spinal mediators of pathological pain induced by both peri-spinal gp120 and sciatic inflammatory neuropathy. Their release from peri-sciatic immune cells is also correlated with the induction and intensity of sciatic inflammatory neuropathy. The two parent R01 grants are aimed at clarifying the immune/glial mechanisms underlying these pain models using immunological, anatomical, molecular, pharmacological, and behavioral approaches. The PI seeks to gain further training in molecular biology techniques (RNase Protection Assays, in situ hybridization, and adenoviral vectors for gene therapy), to enroll in responsible conduct of research coursework, and to continue her education through project-relevant coursework and research forums. Additionally, the released time will foster further professional growth by yielding coherent blocks of time for concentrating on research and review projects.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Scientist Development Award - Research (K02)
Project #
5K02DA015642-05
Application #
7242535
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Thomas, David A
Project Start
2003-06-01
Project End
2008-05-31
Budget Start
2007-06-01
Budget End
2008-05-31
Support Year
5
Fiscal Year
2007
Total Cost
$120,010
Indirect Cost
Name
University of Colorado at Boulder
Department
Psychology
Type
Schools of Arts and Sciences
DUNS #
007431505
City
Boulder
State
CO
Country
United States
Zip Code
80309
Wieseler, Julie; Sprunger, David; Ellis, Amanda et al. (2012) Indwelling supradural catheters for induction of facial allodynia: surgical procedures, application of inflammatory stimuli, and behavioral testing. Methods Mol Biol 851:99-107
Liu, Liang; Coller, Janet K; Watkins, Linda R et al. (2011) Naloxone-precipitated morphine withdrawal behavior and brain IL-1? expression: comparison of different mouse strains. Brain Behav Immun 25:1223-32
Lewis, S S; Hutchinson, M R; Rezvani, N et al. (2010) Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta. Neuroscience 165:569-83
Hutchinson, Mark R; Zhang, Yingning; Shridhar, Mitesh et al. (2010) Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 24:83-95
Hutchinson, M R; Loram, L C; Zhang, Y et al. (2010) Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity. Neuroscience 168:551-63
Hutchinson, M R; Lewis, S S; Coats, B D et al. (2010) Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience 167:880-93
Wieseler, Julie; Ellis, Amanda; Sprunger, David et al. (2010) A novel method for modeling facial allodynia associated with migraine in awake and freely moving rats. J Neurosci Methods 185:236-45
Hains, Leah E; Loram, Lisa C; Weiseler, Julie L et al. (2010) Pain intensity and duration can be enhanced by prior challenge: initial evidence suggestive of a role of microglial priming. J Pain 11:1004-14
Hughes, Travis S; Langer, Stephen J; Virtanen, Salla I et al. (2009) Immunogenicity of intrathecal plasmid gene delivery: cytokine release and effects on transgene expression. J Gene Med 11:782-90
Sloane, E; Langer, S; Jekich, B et al. (2009) Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain. Gene Ther 16:1210-22

Showing the most recent 10 out of 50 publications